Archive · 22 Aug 2025
Panel Criticizes Drug Price Hikes by NPPA, Citing Concerns
A group of government officials is upset because the prices of some important medicines went up by a lot.
The people in charge of making sure medicine prices are fair allowed drug companies to raise the prices of 11 different medicines by up to 50%.
They said they did this because it cost more to make the medicines.
But another group of people says they need to watch the prices of cancer drugs more closely because they are too expensive.
Parliamentary panel criticized NPPA for allowing 50% price hikes on 11 drug formulations.
The price hikes, implemented in October 2024, affected medicines for bacterial infections, asthma, and bipolar disorder.
NPPA justified the hikes to ensure continued availability of essential drugs due to rising production costs.
The government stated NPPA used a mechanism guided by the Committee on Affordable Medicines.
A separate panel urged broader price control on cancer drugs, noting many are not under price regulation.
- Who
- A parliamentary panel and the National Pharmaceutical Pricing Authority (NPPA).
- What
- Parliamentary panel expressed concerns over steep price hikes of essential drugs.
- When
- October 2024.
- Where
- India.
- Why
- To address concerns about rising drug prices.
Parliamentary Panel
NPPA/Government
Price Hikes
Parliamentary Panel
Expresses concerns over the 50% price hikes of essential drugs.
NPPA/Government
NPPA defends hikes to ensure drug availability, using a mechanism based on rising production costs.
Cancer Drug Prices
Parliamentary Panel
Urges broader price control of cancer drugs
NPPA/Government
Government's perspective not provided.
- Panel
- Standing committee on chemicals and fertilizers
- NPPA Action
- Permitted 50% price hikes
- Number of Drugs Affected
- 11
- Medicines Included
- Bacterial infections, asthma, and bipolar disorder
- Justification
- Ensure continued drug availability
